DaVita Inc. DVA
NYSE · United States · Health Services
$174.92-0.27 (-0.15%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
DaVita has delivered a strong 87.2% share price gain over the past three years, which naturally raises a question for anyone looking at the stock today. Is the current valuation still grounded in the earnings power of the dialysis provider, or has the share price moved ahead of what the business is generating? A roughly 87.2% return over three years puts real weight on whether DaVita's earnings profile can support the price investors are paying today. The business leans on recurring...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.